AI drug discovery company Isomorphic Labs has raised a staggering $2.1 billion in funding led by Thrive Capital, with support from Google-backed momentum. The fresh cash is set to expand its AI drug design engine and push timelines for early clinical testing, now expected to start by late 2026, as the company targets faster routes to treating disease.
Alphabet’s AI drug discovery venture, Isomorphic Labs, is reportedly close to raising over $2 billion in a round led by Thrive Capital. The fresh capital would strengthen its drug design engine and support rapid global expansion, highlighting how Alphabet is doubling down on high-stakes AI bets beyond search and ads.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Alphabet’s AI drug discovery startup Isomorphic Labs is reportedly close to raising more than $2 billion in new funding led by Thrive Capital. The fresh cash is set to expand its AI drug design engine and support global growth, reinforcing Alphabet’s push to commercialize advanced AI technology beyond research labs.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
